DOCSLIB.ORG

Final Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Final Program Dear Colleagues, Welcome to the 20th Annual Meeting of the Federation of Clinical Immunology Societies, FOCIS 2020, and the first- ever virtual offering of THE meeting in translational immunology. The FOCIS 2020 Scientific Program is presented by world-renowned leaders from academia and industry presenting new developments in immune therapies, immune diseases, and developing technologies to measure and assess the immune system. Participants will share in best practices for data sharing and assay standardization and the rapid emergence of ever-evolving technologies, and the application of immunological discovery to the challenges facing our global community, that includes the COVID-19 pandemic. This year FOCIS celebrates its 20th anniversary. Since its inception in 2001, FOCIS has continued to strengthen its interdisciplinary approach to clinical immunology and broaden its scope in pursuit of our mission to improve human health through immunology. In our 20th year, FOCIS has 59 Member Societies and 1,000 individual members bridging multiple disciplines with a common focus on immune-mediated disease. The FOCIS Annual Meeting is the leading forum for researchers and clinicians from a multitude of specialties, along with industry and governmental representatives, to come together and share the latest breakthroughs. We value the participation of each of you who have contributed to FOCIS’ success over the past 20 years, and we know that you will continue to empower the efforts of our community to secure the future of the field. We encourage you to get involved in FOCIS. Join FOCIS as a member and join our efforts to promote education, research, and clinical care through translational immunology. Please join me in extending our most heartfelt thanks to the members of the FOCIS 2020 Scientific Program Committee for their time, energy, and expertise that helped put together a world class line up of speakers and topics. We hope you enjoy the fruits of their labor – FOCIS 2020. Thank you, once again, for taking part in FOCIS 2020 and for helping to further the mission of FOCIS. Welcome to our virtual meeting! Sincerely, Mark Anderson, MD, PhD, FOCIS President University of California, San Francisco 2 FOCIS 2020 Supporters FOCIS gratefully acknowledges the support that allows FOCIS to fulfill its mission to foster interdisciplinary approaches to both understand and treat immune-based diseases, and ultimately to improve human health through immunology. DIAMOND SPONSOR PLATINUM SPONSOR GOLD SPONSORS Bio Cell SILVER SPONSORS BRONZE SPONSORS COPPER SPONSORS 3 FOCIS 2020 Scientific Program Committee Jacques Banchereau, PhD Jane Grogan, PhD Kavita Dhodapkar, MD Mark Anderson, MD, PhD The Jackson Laboratory ArsenalBio Emory University University of California, for Genomic Medicine Abstract Chair Abstract Co-Chair San Francisco Chair Jeffrey Bluestone, PhD Silvia Gregori, PhD Nir Hacohen, PhD Jonathan Maltzman, MD, PhD Sonoma Biotherapeutics San Raffaele Telethon Massachusetts Stanford University Institute for Gene Therapy General Hospital Jordan Pober, MD, PhD William Robinson, MD Maria-Grazia Roncarolo, MD Yale University Stanford University Stanford University FOCIS 2020 General Information Evaluations Delegates will receive email reminders and links to the evaluations during the meeting. Evaluations are also accessible through the mobile app. Poster Presentation Hours Thursday, October 29, 2:30 PM – 4:30 PM PT Friday, October 30, 2:30 PM – 4:30 PM PT Release Registration and attendance at, or participation in, FOCIS meetings and other activities constitutes an agreement by the registrant to FOCIS’ use and distribution (both now and in the future) of the registrant or attendee’s image or voice in photographs, videotapes, electronic reproductions and audio tapes of such events and activities. 4 OCTOBER 28-31•2020 VIRTUAL ANNUAL MEETING 7:00 am – 10:20 am Member Society Symposia Environmental Effects on Immune Response Diversity Chairs: Darragh Duffy, PhD, Stanford University; Matthew Albert, MD, PhD, Insitro Organized by Milieu Interieur in partnership with Myriad RBM 7:00 am Differential Effects of Past and Active Smoking on Innate and Adaptive Immunity Darragh Duffy, PhD, Institut Pasteur 7:35 am Early Life Microbiome, Immune Printing and Childhood Health Susan Lynch, PhD, University of California, San Francisco SCIENTIFIC PROGRAM 8:10 am Heterogeneity in Data: A Blessing in Disguise for Accelerating Translational Medicine Purvesh Khatri, PhD, Stanford University All times listed are in US Pacific Daylight 8:45 am Break Time (PT), 7 hours behind UTC. 9:00 am Systems Immunology of Natural and Engineered Wednesday, October 28 Adjuvants John Tsang, PhD, National Institutes of Health 7:00 am – 4:00 pm 9:35 am Study of Natural Immune Variability to Dissect Systems Immunology Course Cytokine Response Pathways (separate registration required) Celine Posseme, Institut Pasteur 8:00 am – 4:30 pm 9:50 am Immune Variation and Protection Against Infection Following Iatrogenic Exposure to Hepatitis C Virus Cancer Immunity and Immunotherapy Course Jamie Sugrue, Trinity College Dublin (separate registration required) 10:05 am Developing a Whole Blood Stimulation System to Predict Glucocorticoid Responsiveness in Patients Organized in with Autoimmune Disease collaboration with Madeleine Stimpson, PhD, University of Bristol 8:30 am – 5:30 pm Basic Immunology in Medicine: Update 2020 Course (separate registration required) 5 Tuesday 7:00 am – 11:00 am 8:45 am Negative Checkpoint Receptors in Organ Specific Going Viral: Modulation of Alloresponses by Viral Autoimmunity and Tolerance Infections Ricardo Pujol Borrell, MD, PhD, Hospital Universitari Chairs: Fadi Issa, DPhil, University of Oxford; Jonathan Vall d'Hebron Maltzman, MD, PhD, Stanford University; Elaine Reed, PhD, 9:15 am Immunotherapy in Noninfectious University of California, Los Angeles Immuno-mediated Uveitis José María Ruiz de Morales, MD, PhD, Complejo Hospitalario Universitario de Leýÿn Organized by 9:45 am Identifying Changes in Peripheral Lymphocyte Subpopulations at the Onset of Adult Type 1 Diabetes and their Long-term Evolution Aina Teniente-Serra, PhD, Hospital Universitari 7:00 am Pseudomonas Aeruginosa and Acute Rejection Germans Trias i Pujol Independently Increase the Risk of Donor-specific 10:00 am The Role of HLA-DR Expression on Monocytes Antibodies after Lung Transplantation and Sepsis Index as Predictive Sepsis Biomarkers Ramsey Hachem, MD, Washington University Bibiana Quiránt Sanchez, MBA, Universitat Autònoma de Barcelona 7:30 am BK Virus and Alloimmune Responses Parmjeet Randhawa, MD, University of Pittsburgh 10:15 am Cytokine Profile of COVID-19-related MIS-C Medical Center Compared with Pre-pandemic Kawasaki Disease and SARS-CoV-2 Specific Immune Complexes 8:00 am T cell Responses to CMV in Transplant Recipients Detection in MIS-C Jonathan Maltzman, MD, PhD, Stanford University Ana Esteve-Sole, Hospital Sant Joan de Déu 8:30 am Flu Specific B cell Populations in Human Tissue 10:30 am Multi-biomarker Integration Enables a Powerful Anoma Nellore, MD, University of Alabama Classification of Long-term Survivors with Normal at Birmingham Allograft Function after Lung Transplantation Albert Mendoza-Valderrey, Vall d'Hebron 9:00 am Break Research Institute 9:30 am Epigenetic Age in Kidney Transplant Patients as a Tool for Improving Age-related Infectious 11:00 am – 2:30 pm Complications of Immunosuppression Member Society Symposia Joanna Schaenman, MD, PhD, University 11:00 am – 2:30 pm of California, Los Angeles Big Data Immunology in Uveitis 10:00 am Evolutionary Responses to Viral Infections and Chairs: Phoebe Lin, MD, PhD, Oregon Health & Science Impact on Human Health University; Kathryn Pepple, MD, PhD, University of Washington Shane Grey, PhD, Garvan Institute of Medical Organized by Research 11:00 am Introduction 10:30 am Question and Answer Period and Wrap Up Phoebe Lin, MD, PhD Oregon Health & Science University 7:00 am – 10:45 am 11:05 am Utility of Single cell RNA Sequencing in Symposium on Tolerance in Transplantation, Noninfectious Uveitis Autoimmunity and Cancer Lynn Hassman, MD, PhD, Washington University Chairs: Eva María Martinez-Cáceres, MD, PhD, Universitat Autònoma de Barcelona; Ricardo Pujol Borrell, MD, PhD, 11:25 am Characterization of Sarcoidosis using Hospital Universitari Vall d'Hebron Metagenomic Deep Sequencing John Gonzales, MD, University of California, San Francisco Organized by 11:45 am Antibiotic Resistance in Azithromycin Treatment in Africa using MDS Thuy Doan, MD, PhD, University of California, San Francisco 7:00 am Spanish Society of Immunology (SEI) actions on the COVID-19 pandemic 12:05 pm Mass Cytometry Multiplexed Imaging Africa Gonzalez, MD, PhD, University of Vigo Valeria Ramaglia, PhD, University of Toronto 7:30 am Trained Immunity as a Therapeutic Target in 12:25 pm Panel Discussion Cancer and Transplantation 12:35 pm Break Jordi Ochando, PhD, Ichan School of Medicine 12:50 pm High Dimensional Profiling and Immune at Mount Sinai Monitoring of Uveitis Patient 8:15 am Cellular Immunotherapy in Autoimmunity and Pulak Nath, PhD, The Jackson Laboratory Multiple Sclerosis 1:10 pm Milieu Intérieur: Defining the Boundaries of Eva María Martinez-Cáceres, MD, PhD, Universitat a Healthy Immune Response for a Better Autònoma de Barcelona Understanding of Disease Darragh Duffy, PhD, Institut Pasteur 6 1:30 pm Using Crowd-sourced Data in Autoimmunity 12:45 pm Break John Tsang, PhD, National Institutes of Health 1:00 pm Mononuclear Phagocytes
Load more

Recommended publications
  • TLR8-Dependent Immune Responses Stimulating Sequence-Specific
    Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses This information is current as Alexandra Forsbach, Jean-Guy Nemorin, Carmen Montino, of September 28, 2021. Christian Müller, Ulrike Samulowitz, Alain P. Vicari, Marion Jurk, George K. Mutwiri, Arthur M. Krieg, Grayson B. Lipford and Jörg Vollmer J Immunol 2008; 180:3729-3738; ; doi: 10.4049/jimmunol.180.6.3729 Downloaded from http://www.jimmunol.org/content/180/6/3729 References This article cites 55 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/180/6/3729.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 28, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses1 Alexandra Forsbach,* Jean-Guy Nemorin,† Carmen Montino,* Christian Mu¨ller,* Ulrike Samulowitz,* Alain P.
    [Show full text]
  • Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods
    pharmaceutics Review Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods Nasir Javaid, Farzana Yasmeen and Sangdun Choi * Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea * Correspondence: [email protected]; Tel.: +82-31-219-2600 Received: 9 July 2019; Accepted: 28 August 2019; Published: 1 September 2019 Abstract: The built-in innate immunity in the human body combats various diseases and their causative agents. One of the components of this system is Toll-like receptors (TLRs), which recognize structurally conserved molecules derived from microbes and/or endogenous molecules. Nonetheless, under certain conditions, these TLRs become hypofunctional or hyperfunctional, thus leading to a disease-like condition because their normal activity is compromised. In this regard, various small-molecule drugs and recombinant therapeutic proteins have been developed to treat the relevant diseases, such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, systemic lupus erythematosus, and allergy. Some drugs for these diseases have been clinically approved; however, their efficacy can be enhanced by conventional or targeted drug delivery systems. Certain delivery vehicles such as liposomes, hydrogels, nanoparticles, dendrimers, or cyclodextrins can be employed to enhance the targeted drug delivery. This review summarizes the TLR signaling pathway, associated diseases and their treatments, and the ways to efficiently deliver the drugs to a target site. Keywords: Toll-like receptor; immunological disease; therapeutic; drug delivery method 1. Introduction The immune system in an organism is the protective system combating pathogenic and/or abnormal conditions. Innate and adaptive immune systems are two basic components in vertebrates. Adaptive immunity is mediated by T and B lymphocytes with the help of their antigen-specific receptors that are encoded as a result of hypermutability and rearrangements in a genomic region of the organism.
    [Show full text]
  • Cx3cr1 Mediates the Development of Monocyte-Derived Dendritic Cells During Hepatic Inflammation
    CX3CR1 MEDIATES THE DEVELOPMENT OF MONOCYTE-DERIVED DENDRITIC CELLS DURING HEPATIC INFLAMMATION. Supplementary material Supplementary Figure 1: Liver CD45+ myeloid cells were pre-gated for Ly6G negative cells for excluding granulocytes and HDCs subsequently analyzed among the cells that were CD11c+ and had high expression of MHCII. Supplementary Table 1 low/- high + Changes in gene expression between CX3CR1 and CX3CR1 CD11b myeloid hepatic dendritic cells (HDCs) from CCl4-treated mice high Genes up-regulated in CX3CR1 HDCs Gene Fold changes P value Full name App 4,01702 5,89E-05 amyloid beta (A4) precursor protein C1qa 9,75881 1,69E-22 complement component 1, q subcomponent, alpha polypeptide C1qb 9,19882 3,62E-20 complement component 1, q subcomponent, beta polypeptide Ccl12 2,51899 0,011769 chemokine (C-C motif) ligand 12 Ccl2 6,53486 6,37E-11 chemokine (C-C motif) ligand 2 Ccl3 4,99649 5,84E-07 chemokine (C-C motif) ligand 3 Ccl4 4,42552 9,62E-06 chemokine (C-C motif) ligand 4 Ccl6 3,9311 8,46E-05 chemokine (C-C motif) ligand 6 Ccl7 2,60184 0,009272 chemokine (C-C motif) ligand 7 Ccl9 4,17294 3,01E-05 chemokine (C-C motif) ligand 9 Ccr2 3,35195 0,000802 chemokine (C-C motif) receptor 2 Ccr5 3,23358 0,001222 chemokine (C-C motif) receptor 5 Cd14 6,13325 8,61E-10 CD14 antigen Cd36 2,94367 0,003243 CD36 antigen Cd44 4,89958 9,60E-07 CD44 antigen Cd81 6,49623 8,24E-11 CD81 antigen Cd9 3,06253 0,002195 CD9 antigen Cdkn1a 4,65279 3,27E-06 cyclin-dependent kinase inhibitor 1A (P21) Cebpb 6,6083 3,89E-11 CCAAT/enhancer binding protein (C/EBP),
    [Show full text]
  • TLR8 Differences Between Human TLR7 and Synthetic TLR Agonists
    Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 Keith B. Gorden, Kevin S. Gorski, Sheila J. Gibson, Ross M. Kedl, William C. Kieper, Xiaohong Qiu, Mark A. Tomai, This information is current as Sefik S. Alkan and John P. Vasilakos of September 29, 2021. J Immunol 2005; 174:1259-1268; ; doi: 10.4049/jimmunol.174.3.1259 http://www.jimmunol.org/content/174/3/1259 Downloaded from References This article cites 36 articles, 14 of which you can access for free at: http://www.jimmunol.org/content/174/3/1259.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 29, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 Keith B. Gorden, Kevin S. Gorski, Sheila J. Gibson, Ross M. Kedl,1 William C.
    [Show full text]
  • TLR8 on Dendritic Cells and TLR9 on B Cells Restrain TLR7-Mediated Spontaneous Autoimmunity in C57BL/6 Mice
    TLR8 on dendritic cells and TLR9 on B cells restrain TLR7-mediated spontaneous autoimmunity in C57BL/6 mice Benoit Desnuesa,b,c,1, Amanda Beatriz Macedoa,b,c,1, Annie Roussel-Quevala,b,c, Johnny Bonnardela,b,c, Sandrine Henria,b,c, Olivier Demariaa,b,c,2, and Lena Alexopouloua,b,c,3 aCentre d’Immunologie de Marseille-Luminy, Aix-Marseille University UM 2, 13288 Marseille, France; bInstitut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1104, 13288 Marseille, France; and cCentre National de la Recherche Scientifique, Unité Mixte de Recherche 7280, 13288 Marseille, France Edited* by Richard A. Flavell, Yale School of Medicine, Howard Hughes Medical Institute, New Haven, CT, and approved December 18, 2013 (received for review August 5, 2013) Systemic lupus erythematosus (SLE) is a complex autoimmune endosomal localization isolate TLR3, TLR7, TLR8, and disease with diverse clinical presentations characterized by the TLR9 away from self-nucleic acids in the extracellular space, still presence of autoantibodies to nuclear components. Toll-like re- self-RNA or -DNA can become a potent trigger of cell activation ceptor (TLR)7, TLR8, and TLR9 sense microbial or endogenous nucleic when transported into TLR-containing endosomes, and such acids and are implicated in the development of SLE. In mice TLR7- recognition can result in sterile inflammation and autoimmunity, deficiency ameliorates SLE, but TLR8- or TLR9-deficiency exacerbates including SLE (4, 15, 16). The connection of the endosomal the disease because of increased TLR7 response. Thus, both TLR8 TLRs with SLE originates mainly from mouse models, where and TLR9 control TLR7 function, but whether TLR8 and TLR9 act in TLR7 signaling seems to play a central role.
    [Show full text]
  • Human TLR7 Or TLR8 Independently Confer Responsiveness to the Antiviral Compound R-848
    CORRESPONDENCE bers of this family (TLR1 to In the quest to identify ligands for TLRs, Human TLR7 or TLR8 TLR10) have been reported to we also screened immunostimulatory synthet- date. TLR2, TLR4 and TLR5 ic compounds for their potential to activate are crucial for the recognition HEK293 cells that were transiently transfect- independently confer of peptidoglycan, lipopolysac- ed with TLR cDNAs and a NF-κB luciferase charide and flagellin, respec- reporter plasmid. We found that R-848 responsiveness to the tively3–5. TLR6 associates with induced NF-κB activation in HEK293 cells TLR2 and recognizes lipopro- transfected with human TLR8 (GenBank antiviral compound teins from mycoplasma6. TLR9 accession number AF245703) in a dose- detects bacterial DNA contain- dependent manner (Fig. 1). In accordance ing unmethylated CpG motifs with the findings of Hemmi et al., human and R-848 and TLR3 activates immune murine TLR7 (GenBank accession numbers cells in response to double- AF240467 and AY035889) also mediate 1, 2, 1 MARION JURK *, FLORIAN HEIL *, JÖRG VOLLMER , stranded RNA7–9. The natural R-848 recognition (Fig. 1)10. TLR7 showed a CHRISTIAN SCHETTER1,ARTHUR M. KRIEG1,HERMANN ligands for TLR1, TLR7, higher sensitivity to R-848, but TLR8 was WAGNER2,GRAYSON LIPFORD1 AND STEFAN BAUER2 TLR8 and TLR10 are not able to induce NF-κB more effectively than known, although a synthetic TLR7 when higher concentrations of R-848 1Coley Pharmaceutical GmbH, Elisabeth-Selbert-Strasse 9, 40764 Langenfeld, Germany and Coley Pharmaceutical Group, Inc., 93 Worcester compound with antiviral activi- were used (Fig. 1). In contrast, HEK293 cells St.,Wellesley, MA 02481, USA.
    [Show full text]
  • A CROSS-SECTIONAL STUDY on the EFFECT of HIV VIRION and BACTERIAL LPS on MEMORY B CELL APOPTOSIS by WEI JIANG Submitted in Part
    A CROSS-SECTIONAL STUDY ON THE EFFECT OF HIV VIRION AND BACTERIAL LPS ON MEMORY B CELL APOPTOSIS by WEI JIANG Submitted in partial fulfillment of requirements for the degree of Master of Science Dissertation Advisor: Dr. Daniel Tisch Department of Epidemiology and Biostatistics CASE WESTEN RESERVE UNIVERSITY May, 2012 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Wei Jiang candidate for the Master of Science degree*. (signed) Daniel Tisch (chair of the committee) Daniel Tisch XiaoFeng Zhu Mark D. Schluchter (date) March27th, 2012 *We also certify that written approval has been obtained for any proprietary material contained therein. 2 Dedicated to my dear husband Zhuang Wan whose patience and encouragement have always given me great support 3 I very much appreciate Dr. PingFu Fu for his support and guidance. I would like to acknowledge my advisor Dr. Daniel Tisch, and committee members Dr. Mark D. Schluchter and Dr. XiaoFeng Zhu. This work was supported by STERIS grant at Case Western Reserve University and NIAID R01AI091526. 4 TABLE OF CONTENTS Abstract 9 Introduction 11 Specific aims 20 Study methods 21 Results 36 Discussion 59 References 66 5 LIST OF TABLES Table 1. Characteristics of HIV-negative control and 36 HIV-infected subjects Table 2. Dependent variable and independent variables 37 Table 3. Correlation test in all subjects 46 Table 4. Correlation test in control subjects 46 Table 5. Correlation test in HIV-infected subjects 47 Table 6. Independent variables include plasma level of FasL, 48 Fas geometric mean expression on memory B cells, or HIV status among all subjects in a linear regression model by forward selection Table 7.
    [Show full text]
  • Reviewed by HLDA1
    Human CD Marker Chart Reviewed by HLDA1 T Cell Key Markers CD3 CD4 CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD8 CD1a R4, T6, Leu6, HTA1 b-2-Microglobulin, CD74 + + + – + – – – CD74 DHLAG, HLADG, Ia-g, li, invariant chain HLA-DR, CD44 + + + + + + CD158g KIR2DS5 + + CD248 TEM1, Endosialin, CD164L1, MGC119478, MGC119479 Collagen I/IV Fibronectin + ST6GAL1, MGC48859, SIAT1, ST6GALL, ST6N, ST6 b-Galactosamide a-2,6-sialyl- CD1b R1, T6m Leu6 b-2-Microglobulin + + + – + – – – CD75 CD22 CD158h KIR2DS1, p50.1 HLA-C + + CD249 APA, gp160, EAP, ENPEP + + tranferase, Sialo-masked lactosamine, Carbohydrate of a2,6 sialyltransferase + – – + – – + – – CD1c M241, R7, T6, Leu6, BDCA1 b-2-Microglobulin + + + – + – – – CD75S a2,6 Sialylated lactosamine CD22 (proposed) + + – – + + – + + + CD158i KIR2DS4, p50.3 HLA-C + – + CD252 TNFSF4,
    [Show full text]
  • Supplementary Table 3. List of Genes Defined in the Literature As Significant in Monocyte-To-Macrophage Differentiation and Polarization
    Supplementary Table 3. List of genes defined in the literature as significant in monocyte-to-macrophage differentiation and polarization. Entrez Reported Symbol Gene Name ID Expression Reference ADAM8 A disintegrin and metalloproteinase domain 8 101 M2 (1) ADK Adenosine kinase 132 M2 (2) AK3 Adenylate kinase 3 50808 M1 (2) ALOX15 Arachidonate 15-lipoxygenase 246 M2 (3) APOL1 Apolipoprotein L, 1 8542 M1 (2) APOL2 Apolipoprotein L, 2 23780 M1 (2) APOL3 Apolipoprotein L, 3 80833 M1 (2) APOL6 Apolipoprotein L, 6 80830 M1 (2) ARG1 Arginase, liver 383 M2 (4) ARG2 Arginase, type II 384 M2 (5) ATF3 Activating transcription factor 3 467 M1 (2) BCL2A1 BCL2-related protein A1 597 M1 (2) BID BH3 interacting domain death agonist 637 Monocyte (2) BIRC3 Baculoviral IAP repeat-containing 3 330 M1 (2) CA2 Carbonic anhydrase II 760 M2 (2) CAT Catalase 847 M2 (6) CAT2 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 6542 M2 (6) CCL1 Chemokine(C-C motif) ligand 1 6346 M2 (4) CCL11 Chemokine ligand 11, Eotaxin 6356 M1 (4) CCL13 Chemokine ligand13, MCP-4 6357 M2 (2) CCL15 Chemokine (C-C motif) ligand 15 6359 M1 (2) CCL17 Chemokine ligand17, TARC 6361 M1 & M2 (4) CCL18 Chemokine ligand 18, MIP-4 6362 M2 (4) CCL19 Chemokine ligand 19, MIP-3B 6363 M1 (2) CCL2 Chemokine ligand 2, MCP1, GDCF-2 6347 Macrophage (2) CCL20 Chemokine ligand 20, MIP-3A 6364 M1 (2) CCL22 Chemokine ligand 22, MDC 6367 M2 (7) CCL23 Chemokine (C-C motif) ligand 23 6368 M2 (2) CCL24 Chemokine ligand 24 6369 M2 (4) CCL25 Chemokine ligand 25 6370 M2 (8) CCL3 Chemokine
    [Show full text]
  • Downloaded Using the R Package “TCGA Biolinks” (12)
    2872 Original Article Systemic immune microenvironment and regulatory network analysis in patients with lung adenocarcinoma Libao Liu1#, Shilei Xu2#, Lei Huang3, Jinyuan He1, Gang Liu4, Shaohong Ma1, Yimin Weng1, Shaohong Huang1 1Department of Cardiothoracic Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; 2Department of General Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; 3Department of Nursing, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; 4Department of Cardiovascular Medicine, First Affiliated Hospital of Sun at-senY University, Guangzhou, China Contributions: (I) Conception and design: L Liu, S Xu, Y Weng, S Huang; (II) Administrative support: L Huang, J He; (III) Provision of study materials or patients: L Huang, G Liu; (IV) Collection and assembly of data: S Ma, Y Weng; (V) Data analysis and interpretation: L Liu, S Xu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Shaohong Huang. Department of Cardiothoracic Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China. Email: [email protected]; Yimin Weng. Department of Cardiothoracic surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China. Email: [email protected]. Background: This study applied a complex bioinformatics analysis to explore the hub regulators and immune network to further elucidate the molecular mechanisms of lung adenocarcinoma (LUAD) immune regulation. Methods: LUAD immunological microenvironment features and microenvironment-related differential expression genes (DEGs) were identified by ESTIMATE algorithm and linear models for microarray analyses (LIMMA), respectively. CIBERSORT and Igraph algorithms were applied to construct the LUAD- related immunocyte infiltration and regulatory network.
    [Show full text]
  • TLR8, TLR9 and Gfi-1 Restrain TLR7-Mediated Lupus
    Université de la Méditerranée Aix-Marseille II Faculté des Sciences de Luminy Ecole Doctorale des Sciences de la Vie et de la Santé Thèse Pour obtenir le grade de Docteur de l’Université d’Aix-Marseille II Discipline : Immunologie Présenté et soutenue publiquement par Amanda Beatriz Rodrigues Barreto de Macedo TLR8, TLR9 and Gfi-1 restrain TLR7-mediated lupus Directrice de thèse : Lena Alexopoulou Soutenue le 17 novembre 2014, devant le jury composé de : Pr Franck Galland Président Dr Sandra Diebold Rapporteur Dr Claire Lugnier Rapporteur Dr Yannis Morel Examinateur Dr Nathalie Lambert Examinateur Dr Lena Alexopoulou Directrice de thèse Résumé Le lupus érythémateux disseminé (LED) est une maladie chronique auto-immune caractérisée par la production d’autoanticorps dirigés contre les antigènes nucléaires. L’étiologie du lupus n’est pas encore claire mais de nombreuses études indiquent un rôle des récepteurs Toll-like (TLR) et leurs voies de signalisation dans l’initiation et la mise en place du LED. Mon projet de thèse avait deux objectifs dont le premier était de comprendre comment le TLR8 et TLR9 contribuent au lupus dépendant de TLR7. Des études antérieures de notre laboratoire ont révélé que le TLR8 murin contrôle la fonction de TLR7 dans les cellules dendritiques et est aussi impliqué dans le lupus. D’autre part, TLR9 contrôle également le lupus dépendant de TLR7. Cependant, leur contribution respective dans le contrôle de TLR7 restait inconnue. En étudiant des souris doublement déficientes pour TLR8 et TLR9, nous avons constaté que les souris TLR8/9-/- présentent une maladie exacerbée avec une splénomégalie accrue, des niveaux d’autoanticorps circulants plus élevés et des dépôts de complexes immuns plus importants au niveau des reins par rapport aux souris déficientes pour TLR8 ou TLR9 uniquement.
    [Show full text]
  • Table S1 : Upregulated Intragraft Gene Transcripts in Only Graft Loss Group
    Table S1 : Upregulated intragraft gene transcripts in only graft loss group (Table S1a), in only functioning allograft group (Table S1b) and in both groups (Table S1c) compared to normal transplant kidney biopsies Table S1a: Transcript Gene Name Adjusted Cluster ID P value 7898793 Complement component 1, q subcomponent, A chain 0.0176 (C1QA),mRNA 7898799 Complement component 1, q subcomponent, C chain (C1QC), 0.0325 transcript variant 1, mRNA 7899394 Chromosome 1 open reading frame 38 (C1orf38), transcript 0.004 variant 3, mRNA 7906435 Duffy blood group, chemokine receptor (DARC), transcript 0.0007 variant 2, mRNA 7906486 SLAM family member 8 (SLAMF8), mRNA 0.0154 7906757 Fc fragment of IgG, low affinity IIa, receptor (CD32) 0.0062 (FCGR2A), transcript variant 1, mRNA 7912145 Tumor necrosis factor receptor superfamily, member 9 0.0128 (TNFRSF9), mRNA 7922773 Neutrophil cytosolic factor 2 (NCF2), transcript variant 1, 0.004 mRNA 7923043 Potassium channel, subfamily T, member 2 (KCNT2), mRNA 0.002 7926410 Mannose receptor, C type 1 (MRC1), mRNA 0.002 7926451 Mannose receptor, C type 1 (MRC1), mRNA 0.002 7934979 Ankyrin repeat domain 1 (cardiac muscle) (ANKRD1), mRNA 0.008 7943749 Layilin (LAYN), mRNA 0.001 7943998 Nicotinamide N-methyltransferase (NNMT), mRNA 0.005 7948455 Membrane-spanning 4-domains, subfamily A, member 6A 0.006 (MS4A6A), transcript variant 1, mRNA 7951217 Matrix metallopeptidase 7 (matrilysin, uterine) (MMP7), 0.029 mRNA 7953200 Cyclin D2 (CCND2), mRNA 0.01 7953901 C-type lectin domain family 12, member A (CLEC12A), 0.004
    [Show full text]